Objective: Irisin has recently been introduced as a novel myokine which reverses visceral obesity and improves glucose metabolism in mice. However, regulation of irisin in humans in relation to renal and metabolic disease has not been comprehensively studied. Design and methods: Serum irisin levels were quantified by ELISA and correlated with anthropometric and biochemical parameters of renal function, glucose and lipid metabolism, as well as inflammation, in 532 patients with stages 1-5 of chronic kidney disease (CKD). Results: Median serum irisin levels adjusted for age, gender, and BMI significantly decreased with increasing CKD stage and lowest concentrations were seen in patients with CKD stage 5. Furthermore, irisin concentrations were associated with facets of the metabolic syndrome including diastolic blood pressure, markers of impaired glucose tolerance, and dyslipidemia in univariate analysis. Moreover, markers of renal function, e.g. glomerular filtration rate, and insulin resistance, e.g. homeostasis model assessment of insulin resistance, remained independently associated with circulating irisin levels in robust multivariate analysis. Conclusions: We show that irisin serum concentrations decrease with increasing CKD stage and are independently and positively predicted by renal function and insulin resistance. The physiological relevance of our findings, as well as the factors contributing to irisin regulation in humans, needs to be further defined in future experiments.
Introduction
The metabolic syndrome and its phenotype including visceral obesity, insulin resistance, type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia contributes significantly to the increasing incidence of cardiovascular disease (CVD) states, especially in Western countries. Various metabolic hormones significantly influence obesity and associated complications. Among those hormones, adipocyte-secreted proteins, so-called adipokines, provide a link between obesity, the metabolic syndrome, and associated CVD. Thus, the adipokine leptin is an appetite-suppressive adipokine upregulated in obesity (1) . Furthermore, leptin induces CVD in various atherosclerosis-prone mouse models (2) . Moreover, adiponectin is an adipokine, improving insulin sensitivity in various animal models of T2DM and obesity. In addition, adiponectin improves vascular function and is inversely associated with metabolic and CVD risk factors (3) .
Besides adipokines, myocyte-secreted proteins, so-called myokines, have also been implicated in obesityassociated metabolic and vascular disease most recently. Among those, irisin is a new myokine that reverses visceral obesity and improves glucose profile (4) . In more detail, Boströ m et al. (4) isolated irisin as a peroxisome proliferator-activated receptor g co-activator-1 a (PGC1a)-induced secreted and circulating protein. Interestingly, irisin stimulates uncoupling protein 1 expression and a broad program of brown-fat-like development (4) . The myokine is induced by exercise in rodents and humans, and increases energy expenditure in mice without influencing movement and food intake leading to improved obesity and glucose homeostasis (4) . Taking the results of this elegant study into consideration, irisin appears as a new myokine and downstream target of PGC1a which improves facets of the metabolic syndrome.
In contrast to extensive studies in animals summarized above, regulation of irisin in humans is far from clearly explained. Thus, no study with sufficient statistical power has included gender, renal function, metabolic, and inflammatory markers combined in its analysis of irisin serum concentrations. To address this issue, we determined circulating irisin concentrations in 532 well-phenotyped subjects with varying degrees of renal function and correlated levels of this myokine with clinical and biochemical measures of renal function, indices of glucose metabolism, and lipid metabolism, as well as inflammation. Our primary hypothesis was that irisin concentrations increase with increasing chronic kidney disease (CKD) stage, suggestive of an at least partial renal elimination of the myokine. The secondary hypotheses were that irisin serum levels are independently predicted by renal function assessed as estimated glomerular filtration rate (eGFR) and that this myocyte-secreted factor is associated with a beneficial metabolic profile in the study cohort.
Subjects and methods

Subjects
The study design has recently been described (5) . In brief, for this cross-sectional study, 532 patients (men, nZ305 and women, nZ227) were consecutively recruited by four nephrology care units including the Department of Endocrinology and Nephrology, University of Leipzig; KfH Renal Unit, Division of Nephrology, Hospital St Georg, Leipzig; and two Outpatient Care Units in Leipzig (Dialysepraxis Leipzig-Zentrum and Leipzig-Burghausen). As all nephrology care units provide hemodialysis service, the number of patients with end-stage renal disease is overrepresented in our cohort. Of the 185 CKD stage 5 patients in the study, 169 were on chronic hemodialysis. The following inclusion and exclusion criteria were applied. Inclusion criteria: age O18 years, non-pregnant provided with written informed consent; exclusion criteria: endstage malignant diseases, acute generalized inflammation, acute infectious disease, and history of drug abuse. In all patients, blood samples were taken after an overnight fast in the morning at the respective care units. Renal function was determined by eGFR being calculated according to the Modification of Diet in Renal Disease formula (6) . Afterwards, the study participants were classified into CKD stages 1-5 according to the National Kidney Foundation -Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines (7) . BMI was determined as weight divided by squared height. Waist-to-hip ratio and waistto-height ratio were calculated after waist and hip circumferences, as well as height, were assessed. Age of the study population ranged from 19 to 92 years and BMI from 14.3 to 49.0 kg/m 2 . Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as previously described (8) . In the study cohort, 218 out of 532 subjects had diabetes mellitus as defined by fasting blood glucose R126 mg/dl, HbA1c R6.5% (9) , or the use of insulin or oral hypoglycemic medications. The study was approved by the Local Ethics Committee and all study participants gave written informed consent before taking part in the study.
Assays
Blood samples were taken after a fasting period of at least 8 h. In hemodialysis patients, blood was obtained just before start of hemodialysis. Serum irisin (Phoenix Pharmaceuticals, Burlingame, CA, USA), leptin (Mediagnost, Reutlingen, Germany), and adiponectin (Mediagnost) were determined with ELISA according to manufacturers' instructions. Serum creatinine, fasting glucose (FG), fasting insulin (FI), triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, and highsensitivity C-reactive protein were measured in a certified laboratory by standard methods. logarithmically transformed. Overall group differences were assessed by one-way ANOVA for independent groups with prior adjustment for age, gender, and BMI. For this purpose, non-standardized residuals with adjustment for age, gender, and BMI were calculated for all parameters and then taken forward as a new variable in the ANOVA. Furthermore, test of linear trend was carried out for all continuous parameters. Moreover, categorical parameters were analyzed using the c 2 -test. Univariate correlations
were assessed by non-parametric Kendall's rank correlation method. Afterwards, multivariate linear regression analyses were carried out using robust methods as offered by the MASS package in R (11) and ANOVA was used to determine P values. Analysis of irisin levels demonstrated that differences were present between batches measured in the laboratory. Therefore, all analyses presented in the manuscript were adjusted for this batch effect if not indicated otherwise. A P value of !0.05 was considered as statistically significant in all analyses.
Results
Irisin serum levels in relation to CKD stage 
Univariate correlations
Serum irisin concentrations in all individuals were positively and significantly correlated with diastolic blood pressure (DBP), eGFR, FG, FI, HOMA-IR, total cholesterol, HDL cholesterol, and LDL cholesterol ( Table 2 ). In contrast, the myokine was significantly and negatively correlated with age and serum creatinine (Table 2) . Furthermore, in a subset of 351 individuals, circulating irisin was not significantly associated with fat mass, lean body mass (LBM), or basic metabolic rate as assessed by bioelectrical impedance analysis in univariate analysis (data not shown).
Multivariate regression analysis
Robust multiple regression analysis revealed that HOMA-IR remained independently and positively associated with circulating irisin in both the full model and the metabolic components-only model (Table 3) . Similarly, renal function markers, i.e. eGFR and creatinine, remained independently associated with the myokine in both full model and renal components-only robust model (Table 3 ). In contrast, the myokine was significantly and independently associated with age, HDL cholesterol, and LDL cholesterol in the full model, but not in the metabolic components-only model (Table 3) .
Discussion
In the current study, we showed that the median serum irisin levels adjusted for age, gender, and BMI significantly decrease with increasing CKD stage and lowest concentrations are seen in patients with CKD stage 5. Furthermore, irisin is significantly and positively correlated with eGFR in uni-and multivariate analyses. These data suggest that irisin is not eliminated by the kidneys and are of current interest for evaluating irisin as a potential pharmacological target. These findings are in contrast to recent results indicating that other metabolic hormones, including several adipokines, show renal clearance. Thus, circulating levels of the adipokines leptin (12), adiponectin (13), retinol-binding protein-4 (14), zinc-a2-glycoprotein (15), adipocyte fatty acid-binding protein (16) , fibroblast growth factor 21 (17), and chemerin (18) are significantly elevated in end-stage renal disease in contrast to the myokine irisin. It needs to be established in future experiments by which mechanisms circulating irisin is being eliminated. In this context, liver enzymes should be evaluated in future studies to determine the possible influence of hepatic clearance on irisin.
As sarcopenia is a frequent finding in CKD and irisin is a myocyte-secreted protein, it can be hypothesized that sarcopenia directly contributes to lower irisin levels in end-stage renal disease. However, be in contrast to this hypothesis, the myokine is not associated with markers of body composition, i.e. fat mass, LBM, and basic metabolic
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www.eje-online.org rate, in a subcohort (nZ351) of our study population. It is interesting to note in this context that Wen et al. (19) demonstrate convincingly that administration of the uremic toxin, indoxyl sulfate, into human skeletal muscle cells or differentiated mouse C2C12 myoblasts decreases protein levels of the irisin precursor FNDC5 in a dose-dependent manner. Most interestingly, only FNDC5 protein levels, but not the upstream target PGC1a, are directly affected (19) . Taking these findings into consideration, it is tempting to speculate that uremic toxins rather than sarcopenia contribute to decreased serum concentrations of irisin in higher CKD stages. Interestingly, median irisin levels significantly decrease by 23% after hemodialysis as compared with predialysis concentrations in a subset of the study population (data not shown). These results are in accordance with the hypothesis that irisin is at least in part dialyzable and it cannot be excluded that the decreased irisin serum levels in CKD stage 5 patients might be in part be due to an effect of hemodialysis on the myokine. However, it needs to be pointed out that in our present study, blood was drawn from end-stage renal disease patients just before the start of hemodialysis.
Besides renal function, irisin is directly associated with various facets of the metabolic syndrome including blood pressure (DBP), glucose metabolism (FG, FI, and HOMA-IR), and dyslipidemia (total cholesterol and LDL cholesterol) in the univariate analyses carried out in the current study. Of these markers, only HOMA-IR remains as a positive predictor of irisin serum concentrations in multivariate analysis in our cohort. The pathophysiological significance of this upregulation, as well as the hormonal networks, influencing irisin serum levels need to be elucidated in future experiments. As irisin counteracts obesity and insulin resistance in animal experiments (4), it is tempting to speculate that the irisin upregulation might be a compensatory mechanism to limit metabolic and vascular consequences of various facets of the metabolic syndrome. Alternatively, irisin resistance similar to insulin and leptin resistance found in this disease state might develop in subjects with the metabolic syndrome (20) . Clearly, these hypotheses need to be tested in future studies. Table 3 Correlation between serum irisin, metabolic components, and renal components adjusted for age and gender using robust regression analysis. Dependent and independent variables are depicted. If a variable was rendered closer to a normal distribution by doing so, then a logarithmic transformation (lg) was used. Table 1 . HDL-C, HDL cholesterol; LDL-C, LDL cholesterol. a Significant correlation.
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In conclusion, irisin concentrations do not increase but decrease with increasing CKD stage suggesting that the myokine is not eliminated by the kidney, in contrast to our primary hypothesis. Furthermore, irisin serum levels are independently and positively predicted by renal function. Moreover, the myokine is not associated with a beneficial metabolic profile in the study cohort, but rather independently and positively associated with HOMA-IR in contrast to our secondary hypotheses. The physiological relevance of these findings, as well as the factors contributing to irisin regulation in humans, needs to be established in future experiments.
